We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 6.93 | 4.79% | 151.52 | 151.85 | 147.62 | 148.89 | 14,473,733 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
The Janssen Pharmaceutical Companies of Johnson & Johnson on Thursday said the U.S. Food and Drug Administration approved its Stelara to treat pediatric patients with severe plaque psoriasis.
The company said Stelara, or ustekinumab, "is the first and only biologic to target interleukin (IL)-12 and IL-23 approved for pediatric psoriasis use."
The company said the FDA's approval was based on results from the Cadmus Junior study, a phase 3 clinical trial of 44 patients that saw 77% achieve clear or almost clear skin at week 12 after two doses.
Stelara had previously been approved to treat adult patients.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 30, 2020 17:34 ET (21:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
